Philips receives FDA clearance for MR-only solution for prostate cancer treatment

Philips has announced FDA clearance and CE mark for its Magnetic Resonance for Calculating ATtenuation (MRCAT) solution, which supports radiation departments that want to rely on MR as their primary imaging modality for prostate cancer treatment.

DotMed